Antimicrobial Treatment of Infective Endocarditis, Caused by Enterococcus Faecalis

The frequency of infective endocarditis (IE) has increased 3 times over the past 30 years. The incidence of IE morbidity is recorded in all countries of the world and in the Russian Federation more than 40 people per 1 million population get sick. One of the most frequent causative agents of infective endocarditis is Enterococcus faecalis (E. faecalis), which takes the third place in the structure of the frequency of IE pathogens. Enterococcal IE remains a disease with high mortality, despite the emergence of new groups of antibacterial drugs. This review includes the results of studies of the efficacy and safety of various antimicrobial regimens of IE caused by E. faecalis. The analysis of data from foreign and native studies of antimicrobial treatment in patients with infective endocarditis, accompanied by enterococcal bacteremia is presented in the review. The search for literature performed by using medical databases: MEDLINE, EMBASE, eLIBRARY. The current review included studies of the efficacy and safety of antimicrobial treatment. The main antibiotic therapy regimens of IE caused by E. faecalis include 2 beta-lactam antibiotics or a combination of ampicillin and gentamicin, according to the results of 5 found studies. Found antimicrobial regimens significantly did not affect mortality. Data from international registries testify to the efficacy and safety of daptomycin monotherapy for enterococcal endocarditis. Linezolid and daptomycin are the main drugs of treating infective endocarditis caused by vancomycin-resistant enterococci. Native studies report of a high level of resistance of enterococcal strains to beta-lactam antibacterial drugs. The duration of fever, the frequency of surgical heart valves interventions, the duration of bacteremia are not fully represented in each of the studies, and it is difficult to evaluate these factors. Ampicillin+ceftriaxone and ampicillin+gentamicin are the main antimicrobial treatment regimens of enterococcal endocarditis. Efficacy of these regimens is not significantly different. Treatment of IE should be carried out taking into the epidemiological situation and the strain resistance.

1. Zarudskiy A.A., Krivoshapova I.I., Prisyazhnyuk E.I. et al. Infective endocarditis at the present stage: clinical and epidemiological characteristics of the disease. Modern Problems of Science and Education. 2018;(3):18 (In Russ.).

2. Vederko N.M., Malayeva E.G., Tsyrulnikova A.N. et al. Infectious endocarditis: Evolution of causative agents and clinical picture. diagnosis, tactics and therapy. Problemy Zdorovja i Jekologii. 2014;4(42):45-51 (In Russ.).

3. Baddour L.M., Wilson W.R., Bayer A.S., et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435-86. DOI:10.1161/CIR.0000000000000296.

4. Soule D., Climo M.M. A Clinician’s Guide to the Treatment of Vancomycin Resistant Enterococci Bacteremia and Endocarditis. Curr Treat Options Infect Dis. 2016;(8):194. DOI:10.1007/s40506-0160082-8.

5. Vergis E.N., Hayden M.K., Chow J.W., et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med. 2001;13(7):484-92. DOI:10.7326/0003-4819-135-7-200110020-00007.

6. Murdoch D.R., Corey G.R., Hoen B., et al. ICE-PCS Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169(5):463-73. DOI:10.1001/archinternmed.2008.603.

7. Di Rosa R., Creti R., Venditti M., et al. Relationship between biofilm formation, the enterococcal surface protein (Esp) and gelatinase in clinical isolates of Enterococcus faecalis and Enterococcus faecium. FEMS Microbiol Lett. 2006;256(1):145-50. DOI:10.1111/j.1574-6968.2006.00112.x.

8. Dahl A., Bruun N.E. Enterococcus faecalis infective endocarditis: focus on clinical aspects. Expert Rev Cardiovasc Ther. 2013;11(9):1247-57. DOI:10.1586/14779072.2013.832482.

9. Salgado C.D., Farr B.M. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol. 2003;24(9):690-8. DOI:10.1086/502271.

10. Newburger J.W., Takahashi M., Gerber M.A., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747-71. DOI:10.1161/01.CIR.0000145143.19711.78.

11. Gavaldà J., Torres C., Tenorio C., et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother. 1999;43(3):639-46. DOI:10.1128/AAC.43.3.639.

12. Gavaldà J., Onrubia P.L., Gomez M.T., et al. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J Antimicrob Chemother. 2003;52(3):514-7. DOI:10.1093/jac/dkg360.

13. Mainardi J.L., Gutmann L., Acar J.F., et al. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother. 1995;39(9):1984-7. DOI:10.1128/aac.39.9.1984.

14. Habib G., Lancellotti, P., Antunes, M.J., et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC) endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075-128. DOI:10.1093/eurheartj/ehv319.

15. Gavaldà J., Len O., Miro J.M., et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med. 2007;146(8):574-9. DOI:10.7326/00034819-146-8-200704170-00008.

16. Fernàndez-Hidalgo N., Almirante B., Gavaldà J., et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis. 2013;56(9):1261-8. DOI:10.1093/cid/cit052.

17. Pericas J.M., Cervera C., Del Rio A., et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect. 2014;20(12):1075-83. DOI:10.1111/1469-0691.

18. El Rafei A., DeSimone D.C., Narichania A.D., et al. Comparison of Dual β-Lactam therapy to penicillin-aminoglycoside combination in treatment of Enterococcus faecalis infective endocarditis. J Infect. 2018;77(5):398-404. DOI:10.1016/j.jinf.2018.06.013.

19. Ceron I., Munoz P., Marín M., et al. Efficacy of daptomycin in the treatment of enterococcal endocarditis: a 5 year comparison with conventional therapy. J Antimicrob Chemother. 2014;69(6):166974. DOI:10.1093/jac/dku004.

20. Levine D.P., Lamp K.C. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med. 2007;120(10):28-33. DOI:10.1016/j.amjmed.2007.07.011.

21. Dohmen P.M., Guleri A., Capone A., et al. Daptomycin for the treatment of infective endocarditis: results from a European registry. J Antimicrob Chemother. 2012;68(4):936-42. DOI:10.1093/jac/dks467.

22. Owens R.C., Donskey C.J., Gaynes R.P., et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(1):19-31. DOI:10.1086/521859.

23. Amberpet R., Sistla S., Parija S.C., et al. Screening for intestinal colonization with vancomycin resistant enterococci and associated risk factors among patients admitted to an adult intensive care unit of a large teaching hospital. J Clin Diagn Res. 2016;10(9):6-9. DOI:10.7860/JCDR/2016/20562.8418.

24. McKinnell J.A., Kunz D.F., Chamot E., et al. Association between vancomycin-resistant enterococci bacteremia and ceftriaxone usage. Infect Control Hosp Epidemiol. 2012;33(7):718-24. DOI:10.1086/666331.

25. Mermel L.A., Allon M., Bouza E., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45. DOI:10.1086/599376.

26. Arias C.A., Contreras G.A., Murray B.E. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect. 2010;16(6):555-62. DOI:10.1111/j.1469-0691.2010.03214.x.

27. Balli E.P., Venetis C.A., Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin resistant enterococcal bacteremia. Animicrob Agents Chemother. 2014;58(2):734-9. DOI:10.1128/AAC.01289-13.

28. Britt N.S., Potter E.M., Patel N., et al. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of Veterans Affairs patients. Clin Infect Dis. 2015;61(6):871-8. DOI:10.1093/cid/civ444.

29. Baddour L.M., Wilson W.R., Bayer A.S. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications. Circulation. 2015;132(15):1435-86. DOI:10.1161/CIR.0000000000000296.

30. Bozhkova S.A. Modern principles of diagnostics and antibacterial therapy of prosthetic joint infection (review). Traumatology and Orthopedics of Russia. 2011;(3):126-36 (In Russ.). DOI:10.21823/2311-2905-2011-0-3-126-136.

31. Anganova E.V., Kryukova N.F., Savilov E.D. Antibiotic resistance of microorganisms isolated from patients of surgical hospital. Acta Biomedica Scientifica. 2016;1(6):177-81 (In Russ.). DOI:10.12737/23821.

32. Kuzmenkov A.Y., Trushin I.V., Avramenko A.A. et al. AMRmap: an online platform for monitoring antibiotic restance. Clinical Microbiology and Antimicrobial Chemotherapy. 2017;2 (19):84-90 (In Russ.).